The Medicines Co. Prepares To Move Into New Commercial Territory
This article was originally published in The Pink Sheet Daily
Executive Summary
With the release of positive Phase III data on the antibiotic oritavancin, the hospital specialist soon could be making a commercial foray into an area outside its current expertise in cardiovascular disease.